| September 1, 2027 |
NVO |
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels |
Trial Milestone |
Phase 3 |
| September 2, 2027 |
IBRX |
IBRX-042 In Participants With HPV-Associated Tumors |
Trial Milestone |
Phase 1 |
| September 3, 2027 |
NVO |
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes |
Trial Milestone |
Phase 2 |
| September 9, 2027 |
NVS |
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation |
Trial Milestone |
Phase 2 |
| September 12, 2027 |
NVO |
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People |
Trial Milestone |
Phase 1 |
| September 13, 2027 |
TAK |
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
LLY |
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
LLY |
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
LLY |
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants |
Trial Milestone |
Phase 1 |
| September 15, 2027 |
ABBV |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
Trial Milestone |
Phase 1 |
| September 15, 2027 |
ARGX |
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis |
Trial Milestone |
Phase 2/Phase 3 |
| September 15, 2027 |
ARGX |
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
SVA |
Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
IONS |
A Study to Assess the Safety, Tolerability and Efficacy of ION775 |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
IONS |
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) |
Trial Milestone |
Phase 1 |
| September 15, 2027 |
IONS |
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2027 |
RARE |
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
ALKS |
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
DFTX |
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
ASND |
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
CYTK |
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
IOVA |
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2027 |
TEVA |
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
KARD |
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy |
Trial Milestone |
Phase 2/Phase 3 |
| September 15, 2027 |
IMVT |
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
CORT |
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
RCUS |
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
Trial Milestone |
Phase 1 |
| September 15, 2027 |
GKOS |
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus |
Trial Milestone |
Phase 4 |
| September 15, 2027 |
TRVI |
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
KYTX |
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis |
Trial Milestone |
Phase 2/Phase 3 |
| September 15, 2027 |
ANRO |
ALTO-100 in Bipolar Disorder With Depression (BD-D) |
Trial Milestone |
Phase 2 |
| September 15, 2027 |
CLYM |
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE) |
Trial Milestone |
Phase 1/Phase 2 |
| September 15, 2027 |
XFOR |
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
AGEN |
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer |
Trial Milestone |
Phase 2 |
| September 17, 2027 |
ARWR |
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
Trial Milestone |
Phase 1/Phase 2 |
| September 23, 2027 |
INCY |
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders |
Trial Milestone |
Phase 2 |
| September 24, 2027 |
TAK |
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
Trial Milestone |
Phase 3 |
| September 24, 2027 |
BIIB |
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) |
Trial Milestone |
Phase 3 |
| September 28, 2027 |
REGN |
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 2/Phase 3 |
| September 28, 2027 |
INCY |
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease |
Trial Milestone |
Phase 3 |
| September 28, 2027 |
ONC |
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| September 29, 2027 |
JNJ |
A Long-term Extension Study of Ustekinumab in Pediatric Participants |
Trial Milestone |
Phase 3 |
| September 30, 2027 |
REGN |
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
INCY |
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib |
Trial Milestone |
Phase 2 |
| September 30, 2027 |
ONC |
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
BIIB |
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
VNDA |
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness |
Trial Milestone |
Phase 3 |
| September 30, 2027 |
BMRN |
Immune Modulation During Palynziq® Treatment in Adults (IMPALA) |
Trial Milestone |
Phase 4 |
| September 30, 2027 |
ALNY |
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
MRNA |
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
GRFS |
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) |
Trial Milestone |
Phase 3 |
| September 30, 2027 |
IMCR |
Study of IMC-P115C in Advanced PRAME-Positive Cancers |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
ALT |
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) |
Trial Milestone |
Phase 2 |
| September 30, 2027 |
MAIA |
THIO Sequenced With Cemiplimab in Advanced NSCLC |
Trial Milestone |
Phase 2 |
| September 30, 2027 |
FATE |
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease |
Trial Milestone |
Phase 1 |
| September 30, 2027 |
CGEM |
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients |
Trial Milestone |
Phase 1 |